Literature DB >> 9501870

Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells.

T Cheng1, W Cao, R Wen, R H Steinberg, M M LaVail.   

Abstract

PURPOSE: To investigate the induction of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) gene expression by prostaglandin E2 (PGE2) in cultured rat Müller cells and to study the mechanism of the induction.
METHODS: Müller cells were obtained from neonatal Sprague-Dawley rat retinas and cultured in essential modified Eagle's medium supplemented with 10% fetal calf serum for up to four passages. Cells were treated with PGE2, protein kinase A (PKA) inhibitors H-89 or SQ 22536, protein kinase C (PKC) inhibitors calphostin C or GF 109203X, PKC activator phorbol 12-myristate 13-acetate (PMA), or the PKA activator forskolin. Northern blot analysis was performed to determine the levels of VEGF and bFGF mRNA.
RESULTS: PGE2 induced VEGF and bFGF mRNA expression in a dose- and time-dependent manner. VEGF and bFGF mRNA reached peaks of 2- and 3.5-fold at 10 microM PGE2. No further increases were observed at 100 microM PGE2. When treated with 10 microM PGE2, the increases in VEGF and bFGF mRNA reached maximum by 2 hours, then slowly declined toward the control level within 24 hours of PGE2 treatment. The inductions of VEGF and bFGF mRNA expression by PGE2 were blocked by the specific PKA inhibitors H-89 (30 microM) or SQ 22536 (500 microM, 1000 microM). Forskolin (10 microM), a cyclic adenosine monophosphate activator, also stimulated VEGF and bFGF mRNA expression. However, the effects of forskolin and PGE2 on VEGF gene expression were not additive, whereas forskolin enhanced the effect of PGE2 on bFGF mRNA expression. The specific PKC inhibitors, GF 109203X (2 microM) and calphostin C (1 microM), did not inhibit PGE2-induced VEGF gene expression, whereas PGE2-induced bFGF expression was blocked by the PKC inhibitor GF 109203X. In addition, downregulation of PKC by PMA (0.8 microM) treatment did not block the induction of VEGF gene expression, whereas it did inhibit the induction of bFGF mRNA expression.
CONCLUSIONS: These results indicate that PGE2 stimulates VEGF and bFGF mRNA expression in cultured rat Müller cells. The induction of VEGF seems to occur through activation of the PKA pathway, whereas that of bFGF occurs through PKA and PKC activation. These findings raise the possibility that endogenous PGE2 stimulates VEGF and bFGF mRNA expression in Müller cells in vivo under conditions in which PGE2 production is increased, such as in injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9501870

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  51 in total

1.  Is cyclooxygenase-2 the alpha and the omega in cancer?

Authors:  S M Prescott
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 2.  Inflammation in diabetic retinopathy.

Authors:  Johnny Tang; Timothy S Kern
Journal:  Prog Retin Eye Res       Date:  2011-05-25       Impact factor: 21.198

Review 3.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

Review 4.  Involvement of Müller glial cells in epiretinal membrane formation.

Authors:  Andreas Bringmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

5.  The safety, pharmacokinetics, and efficacy of intraocular celecoxib.

Authors:  Stephen J Kim; Hassanain Toma; Rohan Shah; Uday B Kompella; Sunil K Vooturi; Jinsong Sheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799

Review 6.  Aspirin and colorectal cancer: back to the future.

Authors:  David Tougeron; Dan Sha; Sashidhar Manthravadi; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2013-12-10       Impact factor: 12.531

7.  A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.

Authors:  Elaine T Lam; Cindy L O'Bryant; Michele Basche; Daniel L Gustafson; Natalie Serkova; Anna Baron; Scott N Holden; Janet Dancey; S Gail Eckhardt; Lia Gore
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

8.  Cyclooxygenase-2 and adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants.

Authors:  Hideki Amano; Izumi Haysahi; Satoko Yoshida; Hirokuni Yoshimura; Masataka Majima
Journal:  Hum Cell       Date:  2002-03       Impact factor: 4.174

9.  Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Heshmatollah Ghanbari; Farzan Kianersi; Seyed Ali Sonbolestan; Mohammad-Ali Abtahi; Mojataba Akbari; Zahra-Alsadat Abtahi; Seyed-Hossein Abtahi
Journal:  Int Ophthalmol       Date:  2016-09-13       Impact factor: 2.031

Review 10.  Phospholipase signalling networks in cancer.

Authors:  Jong Bae Park; Chang Sup Lee; Jin-Hyeok Jang; Jaewang Ghim; Youn-Jae Kim; Sungyoung You; Daehee Hwang; Pann-Ghill Suh; Sung Ho Ryu
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.